(Q36829985)

16 August 2017

1 reference

title

Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? (English)

1 reference

16 August 2017

1 reference

1 reference

Linda Cox

1

1 reference

16 August 2017

John R Cohn

series ordinal

2

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Annals of Allergy, Asthma & Immunology

16 August 2017

published in

1 reference

16 August 2017

volume

98

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

416-426

1 reference

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Long-term inhaled corticosteroids in preschool children at high risk for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Long-term effects of budesonide or nedocromil in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Evaluation of near-fatal reactions to allergen immunotherapy injections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Determinants of patient compliance with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Stinging insect hypersensitivity: a practice parameter update

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Survey of patients after discontinuing venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Discontinuing venom immunotherapy: extended observations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Long-term clinical efficacy of grass-pollen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Booster immunotherapy (BIT)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Long-term efficacy of preseasonal grass pollen immunotherapy in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

A double-blind study of the discontinuation of ragweed immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Mechanisms of immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Increased expression of osteopontin is associated with long-term bee venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Natural history of Hymenoptera venom sensitivity in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Early effect of ultrarush venom immunotherapy on the IgG antibody response.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Clinical guidelines: developing guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Clinical and immunologic follow-up of patients who stop venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

Diagnosis and treatment of insect sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960755-7

7 January 2021

10.1016/S1081-1206(10)60755-7

Identifiers

DOI

1 reference

16 August 2017

1 reference